BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Birnbaum DJ, Finetti P, Lopresti A, Gilabert M, Poizat F, Raoul JL, Delpero JR, Moutardier V, Birnbaum D, Mamessier E, Bertucci F. A 25-gene classifier predicts overall survival in resectable pancreatic cancer. BMC Med 2017;15:170. [PMID: 28927421 DOI: 10.1186/s12916-017-0936-z] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Tesfaye AA, Kamgar M, Azmi A, Philip PA. The evolution into personalized therapies in pancreatic ductal adenocarcinoma: challenges and opportunities. Expert Rev Anticancer Ther. 2018;18:131-148. [PMID: 29254387 DOI: 10.1080/14737140.2018.1417844] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
2 Demirkol Canlı S, Dedeoğlu E, Akbar MW, Küçükkaraduman B, İşbilen M, Erdoğan ÖŞ, Erciyas SK, Yazıcı H, Vural B, Güre AO. A novel 20-gene prognostic score in pancreatic adenocarcinoma. PLoS One 2020;15:e0231835. [PMID: 32310997 DOI: 10.1371/journal.pone.0231835] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
3 Wan Q, Tang J, Lu J, Jin L, Su Y, Wang S, Cheng Y, Liu Y, Li C, Wang Z. Six-gene-based prognostic model predicts overall survival in patients with uveal melanoma. Cancer Biomark 2020;27:343-56. [PMID: 31903983 DOI: 10.3233/CBM-190825] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Zhou C, Zhao Y, Yin Y, Hu Z, Atyah M, Chen W, Meng Z, Mao H, Zhou Q, Tang W, Wang P, Li Z, Weng J, Bruns C, Popp M, Popp F, Dong Q, Ren N. A robust 6-mRNA signature for prognosis prediction of pancreatic ductal adenocarcinoma. Int J Biol Sci 2019;15:2282-95. [PMID: 31595147 DOI: 10.7150/ijbs.32899] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
5 Mao M, Ling H, Lin Y, Chen Y, Xu B, Zheng R. Construction and Validation of an Immune-Based Prognostic Model for Pancreatic Adenocarcinoma Based on Public Databases. Front Genet 2021;12:702102. [PMID: 34335699 DOI: 10.3389/fgene.2021.702102] [Reference Citation Analysis]
6 Wang L, Liu X, Yue M, Liu Z, Zhang Y, Ma Y, Luo J, Li W, Bai J, Yao H, Chen Y, Li X, Feng D, Song X. Identification of hub genes in bladder cancer based on weighted gene co-expression network analysis from TCGA database. Cancer Rep (Hoboken) 2021;:e1557. [PMID: 34541834 DOI: 10.1002/cnr2.1557] [Reference Citation Analysis]
7 Zhu T, Ma Z, Wang H, Wei D, Wang B, Zhang C, Fu L, Li Z, Yu G. Immune-Related Long Non-coding RNA Signature and Clinical Nomogram to Evaluate Survival of Patients Suffering Esophageal Squamous Cell Carcinoma. Front Cell Dev Biol 2021;9:641960. [PMID: 33748133 DOI: 10.3389/fcell.2021.641960] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
8 Wei X, Zhou X, Zhao Y, He Y, Weng Z, Xu C. A 14-gene gemcitabine resistance gene signature is significantly associated with the prognosis of pancreatic cancer patients. Sci Rep 2021;11:6087. [PMID: 33731794 DOI: 10.1038/s41598-021-85680-x] [Reference Citation Analysis]
9 Zhou C, Wang S, Zhou Q, Zhao J, Xia X, Chen W, Zheng Y, Xue M, Yang F, Fu D, Yin Y, Atyah M, Qin L, Zhao Y, Bruns C, Jia H, Ren N, Dong Q. A Long Non-coding RNA Signature to Improve Prognostic Prediction of Pancreatic Ductal Adenocarcinoma. Front Oncol 2019;9:1160. [PMID: 31781487 DOI: 10.3389/fonc.2019.01160] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
10 Birnbaum DJ, Finetti P, Birnbaum D, Mamessier E, Bertucci F. XPO1 Expression Is a Poor-Prognosis Marker in Pancreatic Adenocarcinoma. J Clin Med 2019;8:E596. [PMID: 31052304 DOI: 10.3390/jcm8050596] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
11 Fernández Aceñero MJ, Martínez-Useros J, Díez-Valladares L, García-Botella S, Ortega Medina L, Pérez Aguirre E, de la Serna Esteban S, Latorre E, Neelsen L. Still a place for conventional histopathological analysis in the era of molecular medicine: predicting prognosis of resectable ductal pancreatic adenocarcinoma. Clin Transl Oncol 2019;21:954-9. [PMID: 30565082 DOI: 10.1007/s12094-018-02008-4] [Reference Citation Analysis]
12 Ye J, Wu Y, Cai H, Sun L, Deng W, Liang R, Han A. Development and Validation of a Ferroptosis-Related Gene Signature and Nomogram for Predicting the Prognosis of Esophageal Squamous Cell Carcinoma. Front Genet 2021;12:697524. [PMID: 34764976 DOI: 10.3389/fgene.2021.697524] [Reference Citation Analysis]
13 Wang P, Zhang C, Li W, Zhai B, Jiang X, Reddy S, Jiang H, Sun X. Identification of a robust functional subpathway signature for pancreatic ductal adenocarcinoma by comprehensive and integrated analyses. Cell Commun Signal 2020;18:34. [PMID: 32122386 DOI: 10.1186/s12964-020-0522-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Blair AB, Sorber R, Rozich NS, Burkhart RA. A Qualitative Review of Neoadjuvant Chemotherapy in Resectable Pancreatic Adenocarcinoma. Pancreas 2019;48:973-84. [DOI: 10.1097/mpa.0000000000001376] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
15 Yang J, Shi W, Zhu S, Yang C. Construction of a 6-gene prognostic signature to assess prognosis of patients with pancreatic cancer. Medicine (Baltimore) 2020;99:e22092. [PMID: 32925750 DOI: 10.1097/MD.0000000000022092] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Birnbaum DJ, Bertucci F, Finetti P, Birnbaum D, Mamessier E. Molecular classification as prognostic factor and guide for treatment decision of pancreatic cancer. Biochim Biophys Acta Rev Cancer 2018;1869:248-55. [PMID: 29499330 DOI: 10.1016/j.bbcan.2018.02.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
17 Mao Y, Fu Z, Zhang Y, Dong L, Zhang Y, Zhang Q, Li X, Wang C. A six-microRNA risk score model predicts prognosis in esophageal squamous cell carcinoma. J Cell Physiol 2019;234:6810-9. [PMID: 30387125 DOI: 10.1002/jcp.27429] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
18 Wu M, Li X, Zhang T, Liu Z, Zhao Y. Identification of a Nine-Gene Signature and Establishment of a Prognostic Nomogram Predicting Overall Survival of Pancreatic Cancer. Front Oncol 2019;9:996. [PMID: 31612115 DOI: 10.3389/fonc.2019.00996] [Cited by in Crossref: 46] [Cited by in F6Publishing: 50] [Article Influence: 15.3] [Reference Citation Analysis]
19 Liu H, Li H, Luo K, Sharma A, Sun X. Prognostic gene expression signature revealed the involvement of mutational pathways in cancer genome. J Cancer 2020;11:4510-20. [PMID: 32489468 DOI: 10.7150/jca.40237] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
20 González-Borja I, Viúdez A, Goñi S, Santamaria E, Carrasco-García E, Pérez-Sanz J, Hernández-García I, Sala-Elarre P, Arrazubi V, Oyaga-Iriarte E, Zárate R, Arévalo S, Sayar O, Vera R, Fernández-Irigoyen J. Omics Approaches in Pancreatic Adenocarcinoma. Cancers (Basel) 2019;11:E1052. [PMID: 31349663 DOI: 10.3390/cancers11081052] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
21 Gouirand V, Gicquel T, Lien EC, Jaune-Pons E, Da Costa Q, Finetti P, Metay E, Duluc C, Mayers JR, Audebert S, Camoin L, Borge L, Rubis M, Leca J, Nigri J, Bertucci F, Dusetti N, Lucio Iovanna J, Tomasini R, Bidaut G, Guillaumond F, Vander Heiden MG, Vasseur S. Ketogenic HMG-CoA lyase and its product β-hydroxybutyrate promote pancreatic cancer progression. EMBO J 2022;:e110466. [PMID: 35307861 DOI: 10.15252/embj.2021110466] [Reference Citation Analysis]
22 Yan J, Wu L, Jia C, Yu S, Lu Z, Sun Y, Chen J. Development of a four-gene prognostic model for pancreatic cancer based on transcriptome dysregulation. Aging (Albany NY) 2020;12:3747-70. [PMID: 32081836 DOI: 10.18632/aging.102844] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
23 Jiang M, Wang Z, He X, Hu Y, Xie M, Jike Y, Bo Z, Qin W, Wang F. A Risk-Scoring Model Based on Evaluation of Ferroptosis-Related Genes in Osteosarcoma. Journal of Oncology 2022;2022:1-17. [DOI: 10.1155/2022/4221756] [Reference Citation Analysis]
24 Xue K, Zheng H, Qian X, Chen Z, Gu Y, Hu Z, Zhang L, Wan J. Identification of Key mRNAs as Prediction Models for Early Metastasis of Pancreatic Cancer Based on LASSO. Front Bioeng Biotechnol 2021;9:701039. [PMID: 34485257 DOI: 10.3389/fbioe.2021.701039] [Reference Citation Analysis]
25 Wang P, Li W, Zhai B, Jiang X, Jiang H, Zhang C, Sun X. Integrating high-throughput microRNA and mRNA expression data to identify risk mRNA signature for pancreatic cancer prognosis. J Cell Biochem 2020;121:3090-8. [PMID: 31886578 DOI: 10.1002/jcb.29576] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
26 de Oliveira G, Freire PP, Cury SS, de Moraes D, Oliveira JS, Dal-Pai-Silva M, Reis PP, Carvalho RF. An Integrated Meta-Analysis of Secretome and Proteome Identify Potential Biomarkers of Pancreatic Ductal Adenocarcinoma. Cancers (Basel). 2020;12:716. [PMID: 32197468 DOI: 10.3390/cancers12030716] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
27 Mao Y, Cheng W, Yang Q, Li L, Hu W, Shuang Z, Fan D, Jiang X, Gao F, Li S, Wang W. The enhanced cell cycle related to the response to adjuvant therapy in pancreatic ductal adenocarcinoma. Genomics 2021;114:95-106. [PMID: 34863899 DOI: 10.1016/j.ygeno.2021.11.036] [Reference Citation Analysis]
28 Mao Y, Fu Z, Zhang Y, Dong L, Zhang Y, Zhang Q, Li X, Liu J. A seven-lncRNA signature predicts overall survival in esophageal squamous cell carcinoma. Sci Rep. 2018;8:8823. [PMID: 29891973 DOI: 10.1038/s41598-018-27307-2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 8.0] [Reference Citation Analysis]
29 Mao Y, Fu Z, Dong L, Zheng Y, Dong J, Li X. Identification of a 26-lncRNAs Risk Model for Predicting Overall Survival of Cervical Squamous Cell Carcinoma Based on Integrated Bioinformatics Analysis. DNA Cell Biol 2019;38:322-32. [PMID: 30698466 DOI: 10.1089/dna.2018.4533] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
30 Dong S, Huo H, Mao Y, Li X, Dong L. A risk score model for the prediction of osteosarcoma metastasis. FEBS Open Bio 2019;9:519-26. [PMID: 30868060 DOI: 10.1002/2211-5463.12592] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
31 Sandhu V, Labori KJ, Borgida A, Lungu I, Bartlett J, Hafezi-bakhtiari S, Denroche RE, Jang GH, Pasternack D, Mbaabali F, Watson M, Wilson J, Kure EH, Gallinger S, Haibe-kains B. Meta-Analysis of 1,200 Transcriptomic Profiles Identifies a Prognostic Model for Pancreatic Ductal Adenocarcinoma. JCO Clinical Cancer Informatics 2019. [DOI: 10.1200/cci.18.00102] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
32 Huang H, Zou Y, Zhang H, Li X, Li Y, Deng X, Sun H, Guo Z, Ao L. A qualitative transcriptional prognostic signature for patients with stage I-II pancreatic ductal adenocarcinoma. Transl Res 2020;219:30-44. [PMID: 32119844 DOI: 10.1016/j.trsl.2020.02.004] [Reference Citation Analysis]
33 Hayashi H, Baba H. Precision surgery with the genetic assessment for operable pancreatic cancer beyond the radiological assessment alone. Hepatobiliary Surg Nutr 2021;10:261-3. [PMID: 33898572 DOI: 10.21037/hbsn-20-820] [Reference Citation Analysis]